Blackstone Life Sciences and Boston Scientific launch $455 million partnership to develop next-generation heart pump

Blackstone Life Sciences has entered a collaboration with Boston Scientific, committing $455 million to co‑fund development of a next‑generation miniature heart pump system.

The device, called the Vitalyst Temporary Percutaneous Transvalvular Circulatory Support System, is intended to boost cardiac output and improve blood flow for patients suffering acute myocardial infarction cardiogenic shock, a severe condition where the heart cannot supply enough blood.

This marks the first joint funding of a Boston Scientific product by Blackstone, echoing a similar partnership Blackstone formed with Medtronic in 2020 for diabetes research. The companies aim to address unmet needs in critically ill cardiogenic patients, focusing on efficacy, safety and ease of use for physicians.